1.6-9.6 g/day PO
<16 years old: not recommended
Alzheimers disease, dementia, memory dysfunction, alcoholism, Raynaud's phenomenon, DVT, stroke, tardive dyskinesia, dyslexia, brain injury, vertigo
Approved in many European countries for myoclonus, aging-related conditions (dementia, Alzheimer's)
Some clinical studies show efficacy in dyslexia, brain injury, vertigo
Serious - Use Alternative
Significant - Monitor Closely
Frequency not defined
diarrhea, weight gain, somnolence, insomnia, nervousness, depression, hyperkinesia, rash
Severe renal impairment
Avoid abrupt withdrawal
May impair ability to drive or perform hazardous tasks
Pregnancy & Lactation
Pregnancy Category: contraindicated
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Peak Plasma Time: 1.5 hr
Half-Life: 5 hr
Metabolism: no identified metabolites
Mechanism of Action
Unknown, GABA analog